>Marché mondial du traitement de la sarcopénie, par type de traitement (médicaments, vitamines/compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et taille du marché du traitement de la sarcopénie
Les principaux facteurs à l’origine de la croissance du marché mondial du traitement de la sarcopénie sont la prévalence croissante de cette maladie. En outre, la sensibilisation croissante à la sarcopénie et à ses effets néfastes sur la santé est un autre facteur clé de la croissance du marché. Des facteurs liés au mode de vie tels qu’une mauvaise alimentation et un comportement sédentaire influencent également le marché. Cependant, l’absence de diagnostic standardisé et le coût élevé du traitement et de l’intervention devraient freiner la croissance du marché.
Data Bridge Market Research estime que le marché mondial du traitement de la sarcopénie devrait atteindre la valeur de 4 043 993,94 milliers USD d'ici 2030, à un TCAC de 4,9 % au cours de la période de prévision 2023-2030. Ce rapport de marché couvre également en profondeur l'analyse des prix et les avancées technologiques.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en milliers de dollars américains |
|
Segments couverts |
Type de traitement (médicaments, vitamines/ compléments alimentaires et autres), type (sarcopénie primaire et sarcopénie secondaire), stades (pré-sarcopénie, sarcopénie et sarcopénie sévère), voie d'administration (orale, injectable et autres), sexe (homme et femme), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
États-Unis, Canada, Mexique, Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Pays-Bas, Suisse, Danemark, Norvège, Suède, Pologne, Finlande et reste de l'Europe, Chine, Japon, Australie, Inde, Corée du Sud, Nouvelle-Zélande, Singapour, Thaïlande, Malaisie, Vietnam, Taïwan, Indonésie, Philippines, reste de l'Asie-Pacifique, Brésil, Argentine, reste de l'Amérique du Sud, Afrique du Sud, Arabie saoudite, Émirats arabes unis, Égypte, Israël, Bahreïn, Qatar, Oman et reste du Moyen-Orient et de l'Afrique |
|
Acteurs du marché couverts |
Abbott, Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies. BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA, Healing Pharma India Pvt. Ltd., et entre autres |
Définition du marché
Le traitement de la sarcopénie fait référence au paysage commercial lié aux produits et services visant à prévenir, gérer ou traiter la sarcopénie, une maladie progressive liée à l'âge caractérisée par la perte de masse, de force et de fonction musculaire squelettique, qui commence généralement vers l'âge de 30 ans et s'accélère après 60 ans. La sarcopénie a des conséquences importantes sur la santé globale et la qualité de vie d'un individu. Il en résulte une diminution correspondante de la force et de l'endurance musculaires, ce qui rend les tâches quotidiennes plus difficiles et augmente le risque de chutes et de fractures à mesure que la masse musculaire diminue. De plus, la sarcopénie peut entraîner des changements métaboliques, une résistance à l'insuline et une probabilité accrue d'obésité.
Dynamique du marché mondial du traitement de la sarcopénie
Conducteurs
- Prévalence croissante de la sarcopénie
La sarcopénie est une maladie caractérisée par une perte de masse, de force et de fonction musculaire, en particulier chez les personnes âgées. Ces personnes subissent naturellement une perte progressive de masse et de fonction musculaire, ce qui les prédispose à la sarcopénie à mesure que les personnes vieillissent. Le nombre de personnes à risque de développer une sarcopénie augmente régulièrement avec le vieillissement de la population mondiale. Ce changement démographique entraîne directement la demande d'options de traitement de la sarcopénie. La prévalence croissante de la maladie signifie que davantage de personnes ont besoin d'un diagnostic et d'un traitement, créant ainsi un bassin de patients plus large pour le marché mondial du traitement de la sarcopénie.
Les progrès de la médecine et des soins de santé ont permis aux gens de vivre plus longtemps. Cependant, à mesure que les individus vieillissent, ils sont plus susceptibles de développer une sarcopénie. Cette espérance de vie plus longue contribue à la prévalence globale de la maladie. Les maladies chroniques telles que le diabète, les maladies cardiovasculaires et le cancer peuvent entraîner une perte musculaire et contribuer au développement de la sarcopénie. L’incidence croissante de ces maladies a un impact direct sur la prévalence croissante de la sarcopénie.
- Prise de conscience croissante de la sarcopénie et de ses effets néfastes sur la santé
La prise de conscience croissante de la sarcopénie et de ses effets néfastes sur la santé constitue une avancée significative dans le domaine des soins de santé et du vieillissement. On constate une augmentation significative des recherches et des publications liées à la sarcopénie. Des études scientifiques, des revues médicales et des publications ont fourni aux professionnels de la santé des informations précieuses sur la prévalence, le diagnostic et les conséquences de la maladie. Les écoles de médecine et les programmes de formation ont intégré la sarcopénie dans leurs programmes. Cela garantit que les professionnels de la santé, y compris les médecins, les infirmières et les physiothérapeutes, reçoivent une formation sur la sarcopénie, ses facteurs de risque et les stratégies de gestion.
Divers groupes et organisations de défense des droits s’emploient activement à sensibiliser le public à la sarcopénie. Ces groupes collaborent souvent avec des professionnels de la santé pour informer le public des risques liés à cette maladie et de l’importance d’un diagnostic et d’une intervention précoces. La sarcopénie a fait l’objet d’une couverture accrue dans les médias grand public, notamment dans des articles, des reportages et des documentaires. Cette exposition a contribué à sensibiliser le grand public.
Opportunité
- Initiatives stratégiques des acteurs du marché
Le marché mondial du traitement de la sarcopénie connaît une croissance substantielle, car il s'agit d'une maladie progressive liée à l'âge caractérisée par une perte de masse, de force et de fonction musculaires. Il s'agit d'un problème de santé majeur, en particulier chez les personnes âgées, car il peut entraîner une diminution de la mobilité, un risque accru de chutes et de fractures et une baisse de la qualité de vie globale. C'est pourquoi les principaux acteurs du marché prennent de manière proactive des initiatives stratégiques pour le développement de produits. Cela ouvre ainsi des opportunités d'expansion et d'avancement du marché.
L’initiative stratégique comprend des collaborations et des partenariats avec des institutions de recherche, des organismes de santé et des centres universitaires. Les acteurs du marché peuvent tirer parti de leurs connaissances et de leurs ressources pour accélérer le développement et la commercialisation de traitements contre la sarcopénie en collaborant avec des experts du domaine. De telles collaborations facilitent l’échange de connaissances, l’accès aux populations de patients pour les essais cliniques et la mise en commun d’expertise pour stimuler l’innovation sur le marché.
Retenue / Défi
- Manque de diagnostic standardisé
Les professionnels de santé ne procèdent pas toujours au dépistage de cette maladie, en particulier chez les adultes, ce qui peut entraver une intervention précoce et le démarrage du traitement. Sans diagnostic standardisé, les prestataires de soins de santé peuvent utiliser des critères et des méthodes différents pour identifier la sarcopénie. Cette incohérence peut entraîner des variations dans la prévalence déclarée de la sarcopénie et dans le nombre de cas diagnostiqués, ce qui rend difficile l'évaluation de la taille réelle du marché et de la demande de traitements.
La sarcopénie est une maladie aux multiples facettes qui peut affecter les individus différemment en fonction de facteurs tels que l’âge, le sexe et les comorbidités. Les groupes de patients peuvent être hétérogènes, ce qui rend difficile la réalisation d’essais cliniques et de recherches pour évaluer avec précision l’efficacité du traitement sans critères diagnostiques standardisés. Les essais cliniques sur les traitements de la sarcopénie peuvent utiliser des critères diagnostiques différents, ce qui rend difficile la comparaison des résultats de diverses études. Ce manque de normalisation peut entraver le développement et l’approbation de nouveaux traitements par les organismes de réglementation.
Portée du marché mondial du traitement de la sarcopénie
The global sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Medications
- Vitamin/Dietary Supplements
- Others
On the basis of treatnent type, the market is segmented into vitamin/dietary supplements, medications, and others.
Type
- Primary Sarcopenia
- Secondary Sarcopenia
On the basis of type, the market is segmented into primary sarcopenia and secondary sarcopenia.
Stages
- Pre-Sarcopenia
- Sarcopenia
- Severe Sarcopenia
On the basis of stages, the market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia.
Route of Administration
- Oral
- Injectable
- Others
On the basis of route of administration, the market is segmented into oral, injectable, and others.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
End User
- Hospitals
- Home Healthcare
- Specialty Clinics
- Others
On the basis of end user, the market is segmented into hospitals, home healthcare, specialty clinics, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tenders, retail sales, and others.
Global Sarcopenia Treatment Market Regional Analysis/Insights
The global sarcopenia treatment market is segmented into seven notable segments based on treatment type, type, stages, route of administration, gender, end user, and distribution channel.
The countries covered in this global sarcopenia treatment market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland and Rest of Europe, China, Japan, Australia, India, South Korea, New Zealand, Singapore, Thailand, Malaysia, Vietnam, Taiwan, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Bahrain, Qatar, Oman and Rest of Middle East and Africa.
North America is dominating the global sarcopenia treatment market with the largest market share due to growing awareness and screening and rising healthcare expenditure. U.S. is the dominating country in North America region. Germany is dominating in Europe due to rising prevalence of cancer, and penetration of new technological advancements. Japan is dominating in Asia-Pacific due to to rising R & D activities and patient inclination towards personalized treatment.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales du traitement de la sarcopénie
Le paysage concurrentiel du marché mondial du traitement de la sarcopénie fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les nouvelles initiatives du marché, la présence en Amérique du Nord, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs du marché opérant sur le marché mondial du traitement de la sarcopénie sont Abbott, Nestlé Health Science (une filiale de Nestlé SA), Novartis AG, Sanofi, Haleon Group of Companies. BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma, The Vitamin Company India, Biogen SA, Healing Pharma India Pvt. Ltd., et entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL SARCOPENIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT
5 GLOBAL SARCOPENIA TREATMENT MARKET: REGULATIONS
5.1 REGULATIONS IN U.S.
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN AUSTRALIA
5.4 REGULATIONS IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF SARCOPENIA
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR
6.2 RESTRAINTS
6.2.1 LACK OF STANDARDIZED DIAGNOSIS
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL
7 GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 VITAMIN/DIETARY SUPPLEMENTS
7.2.1 VITAMIN SUPPLEMENTS
7.2.2 PROTEIN SUPPLEMENTS
7.2.3 FATTY ACID SUPPLEMENTS
7.2.4 CREATINE
7.2.5 WHEY PROTEINS
7.2.6 L-CARNITINE
7.2.7 SOY
7.2.8 BETA-ALANINE
7.2.9 OSTARINE
7.2.10 COLLAGEN PEPTIDES
7.2.11 LIGANDROL
7.2.12 BRANCH-CHAIN AMINO ACIDS
7.2.13 HYDROXYMETHYLBUTYRATE (HMB)
7.2.14 MEDIUM CHAIN TRIGLYCERIDES
7.2.15 OTHERS
7.3 MEDICATIONS
7.3.1 OFF LABEL DRUGS
7.3.2 EMERGING DRUGS
7.3.2.1 ACE INHIBITORS
7.3.2.2 APPETITE STIMULANTS
7.3.2.3 ORAL ANTIDIABETIC DRUGS
7.3.2.4 OTHERS
7.4 OTHERS
8 GLOBAL SARCOPENIA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 PRIMARY SARCOPENIA
8.2.1 VITAMIN/DIETARY SUPPLEMENTS
8.2.2 MEDICATIONS
8.2.3 OTHERS
8.3 SECONDARY SARCOPENIA
8.3.1 VITAMIN/DIETARY SUPPLEMENTS
8.3.2 MEDICATIONS
8.3.3 OTHERS
9 GLOBAL SARCOPENIA TREATMENT MARKET, BY STAGES
9.1 OVERVIEW
9.2 PRE-SARCOPENIA
9.3 SARCOPENIA
9.4 SEVERE SARCOPENIA
10 GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INJECTABLES
10.4 OTHERS
11 GLOBAL SARCOPENIA TREATMENT MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 GLOBAL SARCOPENIA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 SPECIALTY CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACIES
13.3.2 ONLINE PHARMACIES
13.3.3 OTHERS
13.4 OTHERS
14 GLOBAL SARCOPENIA TREATMENT MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 FRANCE
14.3.3 U.K.
14.3.4 ITALY
14.3.5 SPAIN
14.3.6 RUSSIA
14.3.7 TURKEY
14.3.8 BELGIUM
14.3.9 NETHERLANDS
14.3.10 SWITZERLAND
14.3.11 DENMARK
14.3.12 NORWAY
14.3.13 SWEDEN
14.3.14 POLAND
14.3.15 FINLAND
14.3.16 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 JAPAN
14.4.2 CHINA
14.4.3 SOUTH KOREA
14.4.4 INDIA
14.4.5 AUSTRALIA
14.4.6 SINGAPORE
14.4.7 THAILAND
14.4.8 MALAYSIA
14.4.9 INDONESIA
14.4.10 PHILIPPINES
14.4.11 VIETNAM
14.4.12 NEW ZEALAND
14.4.13 TAIWAN
14.4.14 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SOUTH AFRICA
14.6.2 SAUDI ARABIA
14.6.3 U.A.E
14.6.4 EGYPT
14.6.5 ISRAEL
14.6.6 OMAN
14.6.7 QATAR
14.6.8 BAHRAIN
14.6.9 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 NOVARTIS AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 PIPELINE PORTFOLIO
17.3.6 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 HALEON GROUP OF COMPANIES.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ASTAREAL CO., LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 BASF SE
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BIOGEN SA
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BIOTHRIVE SCIENCES
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 DSM
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 FERMENTA BIOTECH LIMITED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 HEALING PHARMA INDIA PVT. LTD.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 METAGENICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 THE VITAMIN COMPANY INDIA
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 WELLONA PHARMA
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ARMGO PHARMA, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 PIPELINE PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 BIOPHYTIS
17.17.1 COMPANY SNAPSHOT
17.17.2 PIPELINE PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 DYSTROGEN THERAPEUTICS CORP
17.18.1 COMPANY SNAPSHOT
17.18.2 PIPELINE PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 IMMUNOFORGE INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PIPELINE PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MYMD PHARMACEUTICALS
17.20.1 COMPANY SNAPSHOT
17.20.2 PIPELINE PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 NMD PHARMA A/S
17.21.1 COMPANY SNAPSHOT
17.21.2 PIPELINE PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 ONCOCROSS CO., LTD.
17.22.1 COMPANY SNAPSHOT
17.22.2 PIPELINE PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 OPKO HEALTH, INC.
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PIPELINE PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 REGENERON PHARMACEUTICALS INC.
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PIPELINE PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 REJUVENATE BIOMED NV
17.25.1 COMPANY SNAPSHOT
17.25.2 PIPELINE PORTFOLIO
17.25.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT
TABLE 2 GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 GLOBAL VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 GLOBAL VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 GLOBAL MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 GLOBAL MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 GLOBAL OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 8 GLOBAL OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 9 GLOBAL SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 GLOBAL PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 11 GLOBAL PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 GLOBAL SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 13 GLOBAL SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 GLOBAL SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 15 GLOBAL PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 16 GLOBAL SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 17 GLOBAL SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 19 GLOBAL ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 GLOBAL INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 GLOBAL OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 22 GLOBAL SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 23 GLOBAL MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 GLOBAL FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 25 GLOBAL SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 26 GLOBAL HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 27 GLOBAL HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 28 GLOBAL SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 29 GLOBAL HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 GLOBAL OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 31 GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 32 GLOBAL DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 33 GLOBAL RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 34 GLOBAL RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 35 GLOBAL OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 36 GLOBAL SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 37 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 38 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 39 NORTH AMERICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 NORTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 42 NORTH AMERICA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 45 NORTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 47 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 52 NORTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 53 U.S. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 U.S. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 55 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 57 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 58 U.S. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 U.S. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 U.S. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 U.S. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 U.S. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 63 U.S. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 64 U.S. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 65 U.S. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 66 U.S. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 67 U.S. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 68 U.S. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 69 CANADA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 70 CANADA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 72 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 73 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 74 CANADA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 75 CANADA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 CANADA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 CANADA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 CANADA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 79 CANADA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 80 CANADA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 81 CANADA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 82 CANADA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 83 CANADA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 84 CANADA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 85 MEXICO SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 86 MEXICO MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 87 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 89 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 90 MEXICO VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 MEXICO SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 MEXICO PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 93 MEXICO SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 MEXICO SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 95 MEXICO SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 96 MEXICO SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 97 MEXICO SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 98 MEXICO HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 MEXICO SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 100 MEXICO RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 101 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 102 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 104 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 105 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 106 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 108 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 110 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 111 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 112 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 113 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 114 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 116 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 117 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 121 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 122 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 123 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 124 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 127 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 128 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 129 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 130 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 131 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 132 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 133 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 134 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 135 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 137 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 138 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 140 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 142 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 143 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 144 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 145 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 146 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 148 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 149 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 151 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 153 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 154 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 159 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 160 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 161 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 162 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 164 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 165 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 168 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 169 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 170 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 172 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 175 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 176 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 177 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 178 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 180 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 181 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 182 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 184 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 185 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 186 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 187 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 188 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 189 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 191 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 192 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 193 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 194 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 196 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 197 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 199 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 200 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 201 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 202 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 203 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 204 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 205 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 206 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 207 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 208 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 209 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 210 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 211 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 212 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 213 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 214 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 215 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 217 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 218 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 219 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 220 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 221 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 222 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 223 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 224 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 225 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 226 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 228 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 229 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 230 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 232 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 233 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 234 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 235 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 236 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 237 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 238 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 239 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 240 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 241 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 242 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 243 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 244 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 245 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 247 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 248 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 249 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 250 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 251 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 253 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 254 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 255 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 256 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 257 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 258 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 259 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 260 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 261 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 262 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 263 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 264 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 265 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 266 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 267 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 268 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 269 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 270 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 271 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 272 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 273 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 274 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 275 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 276 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 277 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 278 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 279 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 281 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 282 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 283 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 284 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 285 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 286 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 287 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 288 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 289 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 290 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 291 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 292 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 293 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 294 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 295 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 296 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 297 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 298 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 299 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 300 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 301 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 303 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 304 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 305 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 306 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 307 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 308 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 309 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 310 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 311 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 312 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 313 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 314 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 315 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 316 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 317 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 318 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 319 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 320 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 321 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 322 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 323 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 324 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 325 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 326 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 327 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 328 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 329 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 330 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 331 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 332 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 333 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 334 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 335 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 336 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 337 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 338 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 339 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 340 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 341 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 342 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 343 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 344 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 345 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 346 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 347 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 348 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 349 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 350 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 351 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 352 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 353 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 354 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 355 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 356 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 357 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 358 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 359 ASIA-PACIFIC MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 360 ASIA-PACIFIC OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 361 ASIA-PACIFIC OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 362 ASIA-PACIFIC VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 363 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 364 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 365 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 366 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 367 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 368 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 369 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 370 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 371 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 372 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 373 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 374 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 375 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 376 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 377 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 378 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 379 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 380 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 381 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 382 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 383 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 384 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 385 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 386 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 387 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 388 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 389 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 390 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 391 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 392 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 393 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 394 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 395 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 396 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 397 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 398 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 399 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 400 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 401 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 402 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 403 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 404 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 405 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 406 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 407 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 408 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 409 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 410 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 411 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 413 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 414 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 415 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 416 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 417 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 418 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 419 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 420 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 421 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 422 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 423 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 424 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 425 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 426 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 427 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 428 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 429 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 430 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 431 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 432 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 433 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 434 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 435 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 436 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 437 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 438 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 439 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 440 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 441 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 442 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 443 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 444 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 445 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 446 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 447 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 448 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 449 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 450 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 451 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 452 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 453 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 454 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 455 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 456 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 457 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 458 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 459 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 460 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 461 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 462 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 463 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 464 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 465 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 466 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 467 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 468 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 469 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 470 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 471 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 472 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 473 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 474 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 475 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 476 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 477 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 478 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 479 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 480 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 481 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 482 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 483 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 484 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 485 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 486 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 487 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 488 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 489 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 490 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 491 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 492 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 493 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 494 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 495 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 496 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 497 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 498 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 499 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 500 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 501 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 502 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 503 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 504 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 505 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 506 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 507 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 508 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 509 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 510 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 511 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 512 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 513 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 514 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 515 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 516 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 517 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 518 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 519 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 520 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 521 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 522 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 523 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 524 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 525 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 526 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 527 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 528 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 529 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 530 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 531 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 532 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 533 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 534 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 535 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 536 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 537 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 538 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 539 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 540 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 541 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 542 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 543 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 544 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 545 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 546 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 547 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 548 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 549 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 550 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 551 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 552 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 553 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 554 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 555 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 556 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 557 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 558 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 559 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 560 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 561 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 562 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 563 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 564 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 565 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 566 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 567 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 568 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 569 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 570 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 571 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 572 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 573 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 574 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 575 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 576 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 577 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 578 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 579 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 580 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 581 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 582 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 583 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 584 SOUTH AMERICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 585 SOUTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 586 SOUTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 587 SOUTH AMERICA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 588 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 589 SOUTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 590 SOUTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 591 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 592 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 593 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 594 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 595 SOUTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 596 SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 597 SOUTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 598 BRAZIL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 599 BRAZIL MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 600 BRAZIL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 601 BRAZIL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 602 BRAZIL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 603 BRAZIL VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 604 BRAZIL SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 605 BRAZIL PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 606 BRAZIL SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 607 BRAZIL SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 608 BRAZIL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 609 BRAZIL SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 610 BRAZIL SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 611 BRAZIL HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 612 BRAZIL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 613 BRAZIL RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 614 ARGENTINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 615 ARGENTINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 616 ARGENTINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 617 ARGENTINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 618 ARGENTINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 619 ARGENTINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 620 ARGENTINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 621 ARGENTINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 622 ARGENTINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 623 ARGENTINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 624 ARGENTINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 625 ARGENTINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 626 ARGENTINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 627 ARGENTINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 628 ARGENTINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 629 ARGENTINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 630 REST OF SOUTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 631 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 632 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 633 MIDDLE EAST AND AFRICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 634 MIDDLE EAST AND AFRICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 635 MIDDLE EAST AND AFRICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 636 MIDDLE EAST AND AFRICA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 638 MIDDLE EAST AND AFRICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 639 MIDDLE EAST AND AFRICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 640 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 641 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 642 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 643 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 644 MIDDLE EAST AND AFRICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 645 MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 646 MIDDLE EAST AND AFRICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 647 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 648 SOUTH AFRICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 649 SOUTH AFRICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 650 SOUTH AFRICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 651 SOUTH AFRICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 652 SOUTH AFRICA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 653 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 654 SOUTH AFRICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 655 SOUTH AFRICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 656 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 657 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 658 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 659 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 660 SOUTH AFRICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 661 SOUTH AFRICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 662 SOUTH AFRICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 663 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 664 SAUDI ARABIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 665 SAUDI ARABIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 666 SAUDI ARABIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 667 SAUDI ARABIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 668 SAUDI ARABIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 669 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 670 SAUDI ARABIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 671 SAUDI ARABIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 672 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 673 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 674 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 675 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 676 SAUDI ARABIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 677 SAUDI ARABIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 678 SAUDI ARABIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 679 U.A.E SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 680 U.A.E MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 681 U.A.E OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 682 U.A.E OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 683 U.A.E OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 684 U.A.E VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 685 U.A.E SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 686 U.A.E PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 687 U.A.E SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 688 U.A.E SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 689 U.A.E SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 690 U.A.E SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 691 U.A.E SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 692 U.A.E HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 693 U.A.E SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 694 U.A.E RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 695 EGYPT SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 696 EGYPT MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 697 EGYPT OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 698 EGYPT OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 699 EGYPT OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 700 EGYPT VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 701 EGYPT SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 702 EGYPT PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 703 EGYPT SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 704 EGYPT SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 705 EGYPT SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 706 EGYPT SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 707 EGYPT SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 708 EGYPT HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 709 EGYPT SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 710 EGYPT RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 711 ISRAEL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 712 ISRAEL MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 713 ISRAEL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 714 ISRAEL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 715 ISRAEL OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 716 ISRAEL VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 717 ISRAEL SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 718 ISRAEL PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 719 ISRAEL SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 720 ISRAEL SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 721 ISRAEL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 722 ISRAEL SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 723 ISRAEL SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 724 ISRAEL HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 725 ISRAEL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 726 ISRAEL RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 727 OMAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 728 OMAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 729 OMAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 730 OMAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 731 OMAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 732 OMAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 733 OMAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 734 OMAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 735 OMAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 736 OMAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 737 OMAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 738 OMAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 739 OMAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 740 OMAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 741 OMAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 742 OMAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 743 QATAR SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 744 QATAR MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 745 QATAR OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 746 QATAR OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 747 QATAR OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 748 QATAR VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 749 QATAR SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 750 QATAR PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 751 QATAR SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 752 QATAR SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 753 QATAR SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 754 QATAR SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 755 QATAR SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 756 QATAR HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 757 QATAR SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 758 QATAR RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 759 BAHRAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 760 BAHRAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 761 BAHRAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 762 BAHRAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 763 BAHRAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 764 BAHRAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 765 BAHRAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 766 BAHRAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 767 BAHRAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 768 BAHRAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)
TABLE 769 BAHRAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 770 BAHRAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 771 BAHRAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 772 BAHRAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 773 BAHRAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 774 BAHRAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 775 REST OF MIDDLE EAST AND AFRICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL SARCOPENIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL SARCOPENIA TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 GLOBAL SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL SARCOPENIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL SARCOPENIA TREATMENT MARKET
FIGURE 14 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022
FIGURE 15 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 17 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, 2022
FIGURE 19 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, 2022
FIGURE 23 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)
FIGURE 24 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 25 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 26 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)
FIGURE 28 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)
FIGURE 29 GLOBAL SARCOPENIA TREATMENT MARKET: LIFELINE CURVE
FIGURE 30 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, 2022
FIGURE 31 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 32 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 33 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 34 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, 2022
FIGURE 35 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 36 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 40 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 41 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 42 GLOBAL SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 43 GLOBAL SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%)
FIGURE 44 NORTH AMERICA SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 45 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 46 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
